Bacillus coagulans (spore-forming probiotic)

Q: Can children take Bacillus coagulans?

One trial gave Unique IS2 chewable tablets once daily for 8 weeks to 141 children aged 4–12 with IBS and found less pain and better stools than placebo. Premature infants are a different case: NCCIH reports severe or fatal infections in premature infants given probiotics.

Q: Is it safe to take Bacillus coagulans every day?

Trials of 1–6 billion CFU a day for 4 to about 13 weeks reported no severe adverse events, but longer use has not been studied. NCCIH says infection risk is higher with severe illness or a weakened immune system, and one Health Canada licence contraindicates immune-compromised conditions.

Q: How is Bacillus coagulans different from other probiotics?

It forms spores, unlike most Lactobacillus and Bifidobacterium products. NCCIH notes that effects found for one probiotic do not carry over to others, and B. coagulans results are strain-specific.

Q: Which Bacillus coagulans strain has the most evidence for IBS?

Unique IS2. A 2026 strain-specific meta-analysis found it improved core IBS symptoms across two placebo-controlled trials (249 adults and children), while MTCC 5856 improved only IBS quality of life. A 2023 network meta-analysis also ranked MTCC 5856 and Unique IS2 among the best strains for abdominal pain. Maker-linked trials dominate.

Q: Why do labels say Heyndrickxia coagulans?

The species has been reclassified; recent trials name it Heyndrickxia (Bacillus) coagulans, so labels may use either name.

Also called Heyndrickxia coagulans, Weizmannia coagulans, Lactobacillus sporogenes, Unique IS2, MTCC 5856, LactoSpore.

Best grade B across 9 graded outcomes Other Last checked Oct 21, 2026

The short answer

From 15 sources

Bacillus coagulans is a spore-forming probiotic bacterium, recently renamed Heyndrickxia coagulans. Strain-specific trials, most with authors from ingredient makers, report better IBS symptoms, stool frequency and bloating at 1 to 6 billion CFU a day. Results belong to each strain, and independent replication is limited.

Every graded outcome on this page

9 rows · line = participants

Grade BIBS symptoms (Unique IS2)IBSn 249
Grade CBowel movement frequency and stool consistency in healthy adultsConstipationn 144
Grade CStool frequency and consistency in healthy adults with GI complaintsBowel functionn 111
Grade CBowel movements in functional constipationConstipationn 100
Grade CGas and bloating symptomsBloatingn 70
Grade DCold symptoms (upper respiratory tract infection)Coldsn 79
Grade DSleep efficiency and qualitySleepn 78
Grade DIBS symptoms and stool consistencyIBSn 40
Grade DDiarrhoea-predominant IBS symptomsIBSn 36
6 more graded outcomes, in the evidence chapter

Key facts

What it is: A spore-forming, lactic-acid-producing probiotic species; MTCC 5856 is described as thermostable⁴
Strain matters: A 2023 network meta-analysis (81 RCTs, 9,253 adults with IBS) ranked MTCC 5856 and Unique IS2 among the most effective strains for abdominal pain⁷
2026 meta-analysis: A strain-specific meta-analysis found Unique IS2 improved core IBS symptoms (2 trials, adults and children) and MTCC 5856 improved IBS quality of life⁸
Beyond the gut: Single small trials report better sleep efficiency (IDCC 1201, 5 billion CFU) and fewer cold symptoms (SANK70258); grade D^14,15
Funding: Every trial listed here has authors from, or funding by, companies: ingredient makers (Unique Biotech, Sami-Sabinsa, Kerry, Advanced Enzyme Technologies, Ildong Bioscience, Mitsubishi Chemical) or, for the 2025 Unique IS2 trial, PepsiCo and a contract research organisation^{1,2,3,4,5,6,13,14,15}
Canada: Health Canada's probiotics monograph excludes B. coagulans, so products are licensed individually; one licence contraindicates immune-compromised conditions^11,10

What it is

Bacillus coagulans is a spore-forming, lactic-acid-producing bacterium sold as a shelf-stable probiotic supplement.

How it works

Proposed

Like other probiotics, B. coagulans is proposed to work by shifting the gut's microbial community, producing beneficial substances and influencing immune responses; NCCIH notes different probiotics may act in different ways. In a 2025 trial, the GBI-30, 6086 strain raised Bacteroides and lowered Clostridium, Blautia and Ruminococcus without broader microbiome change.^9,3

Forms, side by side

6 forms named in our sources. The rest show what our data holds, and say plainly where it holds nothing yet.

Bacillus coagulans (spore-forming probiotic) forms compared

6 forms

Bacillus coagulans (spore-forming probiotic) forms compared: 6 forms by 3 attributes. Empty cells are labelled No data yet, or Not graded in the evidence row.
6 forms	Unique IS2 (MTCC 5260)	MTCC 5856 (LactoSpore)	GBI-30, 6086 (BC30)	LBSC (DSM 17654)	IDCC 1201	SANK70258
Absorption in people	No head-to-head human data between strains.⁸	No head-to-head human data between strains.⁷	No head-to-head human data between strains.³	No head-to-head human data between strains.⁶	No head-to-head human data between strains.¹⁴	No head-to-head human data between strains.¹⁵
GI tolerance	No severe adverse events in the adult IBS trial; safe and well tolerated over 4 weeks in healthy adults.^1,13	No adverse events reported in the bloating trial.⁴	Well tolerated in a 4-week trial in healthy adults.³	No serious adverse events in an 80-day IBS trial.⁶	No significant safety concerns in a 4-week sleep trial.¹⁴	No tolerance data in the trial abstract.¹⁵
Studied for	IBS in adults and children, functional constipation, infrequent bowel movements in healthy adults	Diarrhoea-predominant IBS, gas and bloating	Bowel function in healthy adults with GI complaints	IBS	Sleep in adults with sleep disturbance	Cold symptoms and immune markers in healthy adults

Unique IS2 (MTCC 5260)
Absorption in people
No head-to-head human data between strains.⁸
GI tolerance
No severe adverse events in the adult IBS trial; safe and well tolerated over 4 weeks in healthy adults.^1,13
Studied for
IBS in adults and children, functional constipation, infrequent bowel movements in healthy adults
MTCC 5856 (LactoSpore)
Absorption in people
No head-to-head human data between strains.⁷
GI tolerance
No adverse events reported in the bloating trial.⁴
Studied for
Diarrhoea-predominant IBS, gas and bloating
GBI-30, 6086 (BC30)
Absorption in people
No head-to-head human data between strains.³
GI tolerance
Well tolerated in a 4-week trial in healthy adults.³
Studied for
Bowel function in healthy adults with GI complaints
LBSC (DSM 17654)
Absorption in people
No head-to-head human data between strains.⁶
GI tolerance
No serious adverse events in an 80-day IBS trial.⁶
Studied for
IBS
IDCC 1201
Absorption in people
No head-to-head human data between strains.¹⁴
GI tolerance
No significant safety concerns in a 4-week sleep trial.¹⁴
Studied for
Sleep in adults with sleep disturbance
SANK70258
Absorption in people
No head-to-head human data between strains.¹⁵
GI tolerance
No tolerance data in the trial abstract.¹⁵
Studied for
Cold symptoms and immune markers in healthy adults

What the human research says

Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.

Trial map

9 graded outcomes, largest study first

All 9 graded outcomes found an improvement. The largest, a 2026 meta-analysis of 249 people on IBS symptoms (Unique IS2), found an improvement.

By sizeTable

1IBS symptoms (Unique IS2)

Improved · Grade B · Meta-analysis, 249 people, 2026

2 placebo-controlled trials of Unique IS2 in IBS: adults aged 18–60 (108 in the meta-analysis of 136 randomised) and children aged 4–12 (141)

Dose, result and source

Every graded outcome on this page, largest study first
Outcome	Found	People	Study	Who was studied
IBS symptoms (Unique IS2)	Improved	249	Grade B · Meta-analysis, 2026	2 placebo-controlled trials of Unique IS2 in IBS: adults aged 18–60 (108 in the meta-analysis of 136 randomised) and children aged 4–12 (141)
Bowel movement frequency and stool consistency in healthy adults	Improved	144	Grade C · RCT, 2025	Healthy adults with 3 to fewer than 7 spontaneous bowel movements a week during a 2-week run-in
Stool frequency and consistency in healthy adults with GI complaints	Improved	111	Grade C · RCT, 2025	Healthy adults aged 18–65 in China with functional gastrointestinal complaints
Bowel movements in functional constipation	Improved	100	Grade C · RCT, 2020	Adults with functional constipation
Cold symptoms (upper respiratory tract infection)	Improved	79	Grade D · RCT, 2024	Healthy working adults aged 20–65 in Japan, preferring those with low salivary IgA
Sleep efficiency and quality	Improved	78	Grade D · RCT, 2026	Adults aged 19–65 with sleep disturbance (Korea); 80 randomised, 78 completed
Gas and bloating symptoms	Improved	70	Grade C · RCT, 2023	Adults with functional gas and bloating at hospitals in southern India
IBS symptoms and stool consistency	Improved	40	Grade D · RCT, 2021	Adults aged 18–65 with IBS (Rome IV)
Diarrhoea-predominant IBS symptoms	Improved	36	Grade D · Pilot RCT, 2016	Newly diagnosed adults with diarrhoea-predominant IBS at three centres, on standard care

Every graded row

9 rows

Form tested

Showing 9 of 9 outcomes. Human trials only.

Grade BIBS symptoms (Unique IS2)IBSCore IBS symptoms improvedMeta-analysis · 2 studies
n 249 · 2026

Improved Pooled, Unique IS2 reduced abdominal pain, bloating, urgency, incomplete evacuation, straining, flatulence, bowel-habit dissatisfaction and overall IBS symptoms, and normalised stool consistency more often than placebo; adverse effects did not differ.

Design: Meta-analysis, 2 studies, n = 249, 2026
Population: 2 placebo-controlled trials of Unique IS2 in IBS: adults aged 18–60 (108 in the meta-analysis of 136 randomised) and children aged 4–12 (141)
Form: B. coagulans Unique IS2
Dose: 2 billion CFU daily in adults; one chewable tablet daily in children
Duration: 8 weeks
Source: Reference 8 · PubMed 41682832 (opens PubMed)

Grade CBowel movement frequency and stool consistency in healthy adultsConstipationImprovedRCT
n 144 · 2025

Improved Bowel movement frequency rose versus placebo (P = 0.037) and stool consistency improved (P = 0.018), driven by fewer hard stools (P = 0.001). GI symptoms, quality of life and gut microbiota did not change. Safe and well tolerated.

Design: RCT, n = 144, 2025
Population: Healthy adults with 3 to fewer than 7 spontaneous bowel movements a week during a 2-week run-in
Form: B. coagulans Unique IS2
Dose: 2 billion CFU daily
Duration: 4 weeks
Source: Reference 13 · PubMed 40456531 (opens PubMed)

Grade CStool frequency and consistency in healthy adults with GI complaintsBowel functionImprovedRCT
n 111 · 2025

Improved More stools per week (p=0.036), better stool consistency (p<0.001) and fewer participants with constipation (p<0.001) than placebo; minor microbiome shifts; well tolerated.

Design: RCT, n = 111, 2025
Population: Healthy adults aged 18–65 in China with functional gastrointestinal complaints
Form: B. coagulans GBI-30, 6086 (BC30)
Dose: 1 billion CFU daily
Duration: 4 weeks
Source: Reference 3 · PubMed 40707016 (opens PubMed)

Grade CBowel movements in functional constipationConstipationImprovedRCT
n 100 · 2020

Improved Bowel movements increased significantly versus placebo (p<0.001); 98% vs 74% reached normal stool consistency, with less incomplete evacuation, painful defecation and abdominal pain.

Design: RCT, n = 100, 2020
Population: Adults with functional constipation
Form: B. coagulans Unique IS2
Dose: 2 billion CFU once daily
Duration: 4 weeks
Source: Reference 2 · PubMed 30911991 (opens PubMed)

Grade CGas and bloating symptomsBloatingImprovedRCT
n 70 · 2023

Improved GSRS indigestion score fell from 8.91 to 3.06 vs 9.42 to 8.43 with placebo (p<0.001); global evaluation scores also improved more. 66 of 70 completed; no adverse events reported.

Design: RCT, n = 70, 2023
Population: Adults with functional gas and bloating at hospitals in southern India
Form: B. coagulans MTCC 5856 (LactoSpore)
Dose: 2 billion spores daily
Duration: 4 weeks
Source: Reference 4 · PubMed 36862903 (opens PubMed)

Grade DCold symptoms (upper respiratory tract infection)ColdsImprovedRCT
n 79 · 2024

Improved Runny nose, nasal congestion, sneezing and sore throat scores and the cumulative days with these symptoms were lower than with placebo; salivary secretory IgA was higher and NK-cell activity tended to be higher.

Design: RCT, n = 79, 2024
Population: Healthy working adults aged 20–65 in Japan, preferring those with low salivary IgA
Form: H. coagulans SANK70258
Dose: Capsule of 1 billion CFU (67 mg)
Duration: 8 weeks
Source: Reference 15 · PubMed 38957464 (opens PubMed)

Grade DSleep efficiency and qualitySleepImprovedRCT
n 78 · 2026

Improved Polysomnography sleep efficiency rose 13.71 percentage points vs −0.15 with placebo (p = 0.002); total sleep time rose 49.6 min vs −0.5 min and wake after sleep onset fell 44.4 min; PSQI improved more (−3.67 vs −1.64). No significant safety concerns.

Design: RCT, n = 78, 2026
Population: Adults aged 19–65 with sleep disturbance (Korea); 80 randomised, 78 completed
Form: B. coagulans IDCC 1201
Dose: 5 billion CFU daily
Duration: 4 weeks
Source: Reference 14 · PubMed 42196985 (opens PubMed)

Grade DIBS symptoms and stool consistencyIBSImprovedRCT
n 40 · 2021

Improved Digestive symptom scores (bloating/cramping, pain, diarrhoea, constipation and others) improved significantly versus placebo; 38 completed per protocol; no serious adverse events.

Design: RCT, n = 40, 2021
Population: Adults aged 18–65 with IBS (Rome IV)
Form: B. coagulans LBSC (DSM 17654)
Dose: 6 billion CFU daily
Duration: 80 days
Source: Reference 6 · PubMed 33545934 (opens PubMed)

Grade DDiarrhoea-predominant IBS symptomsIBSImprovedPilot RCT
n 36 · 2016

Improved Bloating, vomiting, diarrhoea, abdominal pain and stool frequency fell significantly more than with placebo (p<0.01), and quality of life improved.

Design: Pilot RCT, n = 36, 2016
Population: Newly diagnosed adults with diarrhoea-predominant IBS at three centres, on standard care
Form: B. coagulans MTCC 5856
Dose: 2 billion CFU daily
Duration: 90 days
Source: Reference 5 · PubMed 26922379 (opens PubMed)

What the numbers add up to

Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.

Evidence is strain-by-strain

Pooled analyses credit specific strains (Unique IS2, MTCC 5856) with specific IBS outcomes, so results for one B. coagulans product do not transfer to another.^7,8

Maker-run trials dominate

All nine trials listed here have authors from, or funding by, companies, most of them the makers of the strain tested (Unique Biotech, Sami-Sabinsa, Kerry, Advanced Enzyme Technologies, Ildong Bioscience, Mitsubishi Chemical).^{1,2,3,4,5,6,13,14,15}

Studied doses

Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.

Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.

Doses studied in human trials

Doses studied in human trials ranged from 1 billion CFU a day (GBI-30, 6086) to 6 billion CFU a day (LBSC) for 4 weeks to about 13 weeks; most trials used 2 billion CFU a day, and a sleep trial used 5 billion CFU a day.^{1,2,3,4,5,6,14}

When trials measured an effect

2 outcomes

How long trials ran before effects were measured
Outcome	Measured at	Basis
Stool consistency (Unique IS2)	Better each week from week 1 within the probiotic group; better than placebo at week 4	4-week trial in 144 healthy adults with infrequent bowel movements¹³
Sleep efficiency (IDCC 1201)	Week 4 (primary endpoint)	Polysomnography before and after 4 weeks, 80 adults¹⁴

Interactions and safety

Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.

Interactions

0 agents

None found in our sources.

Check with what you take

Kept on this device only

Add what you take. We list every interaction our evidence profiles cite between Bacillus coagulans and your picks, and between your picks.

Add a supplement or medicine

Most cited:

Add a supplement or medicine you take to check it against Bacillus coagulans.

Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.

Who should be careful

5 groups

Weakened immune system or serious illness: NCCIH says the risk of harm from probiotics, including infection, is greater with severe illness or a compromised immune system. A Health Canada-licensed B. coagulans product is contraindicated with immune-compromised conditions such as AIDS, lymphoma or long-term corticosteroid use.^9,10
Premature infants: Severe or fatal infections have been reported in premature infants given probiotics, and the FDA has warned health care providers about this risk (NCCIH).⁹
Fever, bloody diarrhoea or severe abdominal pain: Health Canada licence wording: consult a health care practitioner before use with fever, vomiting, bloody diarrhoea or severe abdominal pain, and stop if digestive upset persists beyond 3 days.¹⁰
Pregnancy and breastfeeding: Our safety sources give no B. coagulans-specific data for pregnancy or breastfeeding; NCCIH advises consulting a health care provider before using any probiotic supplement.⁹
Product contents: NCCIH notes some probiotic products have contained microorganisms other than those on the label, which can pose health risks.⁹

Frequently asked questions

Short answers to common questions; the numbers link to the sources below.

Common questions

5 answers

Can children take Bacillus coagulans?

One trial gave Unique IS2 chewable tablets once daily for 8 weeks to 141 children aged 4–12 with IBS and found less pain and better stools than placebo. Premature infants are a different case: NCCIH reports severe or fatal infections in premature infants given probiotics.^12,9

Is it safe to take Bacillus coagulans every day?

Trials of 1–6 billion CFU a day for 4 to about 13 weeks reported no severe adverse events, but longer use has not been studied. NCCIH says infection risk is higher with severe illness or a weakened immune system, and one Health Canada licence contraindicates immune-compromised conditions.^1,6,13,9,10

How is Bacillus coagulans different from other probiotics?

It forms spores, unlike most Lactobacillus and Bifidobacterium products. NCCIH notes that effects found for one probiotic do not carry over to others, and B. coagulans results are strain-specific.^9,7

Which Bacillus coagulans strain has the most evidence for IBS?

Unique IS2. A 2026 strain-specific meta-analysis found it improved core IBS symptoms across two placebo-controlled trials (249 adults and children), while MTCC 5856 improved only IBS quality of life. A 2023 network meta-analysis also ranked MTCC 5856 and Unique IS2 among the best strains for abdominal pain. Maker-linked trials dominate.^8,7

Why do labels say Heyndrickxia coagulans?

The species has been reclassified; recent trials name it Heyndrickxia (Bacillus) coagulans, so labels may use either name.³

Sources

15 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.

Sources cited on this page

15 sources

1Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.RCT Sci Rep, 2019 · PMID 31434935
2Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study.RCT Probiotics Antimicrob Proteins, 2020 · PMID 30911991
3Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial.RCT Benef Microbes, 2025 · PMID 40707016
4The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study.RCT Medicine (Baltimore), 2023 · PMID 36862903
5Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.Pilot RCT Nutr J, 2016 · PMID 26922379
6Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant].RCT Medicine (Baltimore), 2021 · PMID 33545934
7Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.Meta-analysis Nutrients, 2023 · PMID 37686889
8Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.Meta-analysis J Clin Med, 2026 · PMID 41682832
9Probiotics: Usefulness and Safety (last updated August 2019)Fact sheet National Center for Complementary and Integrative Health (NCCIH), 2019 · nccih.nih.gov
10Licensed Natural Health Products Database: Bacillus Coagulans BC99 (NPN 80142858), risk informationLabel Health Canada, 2025 · health-products.canada.ca
11Natural Health Product Monograph: Probiotics (April 24, 2026)Guideline Health Canada (NNHPD), 2026 · webprod.hc-sc.gc.ca
12Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study.RCT Benef Microbes, 2018 · PMID 29695183
13Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial.RCT Benef Microbes, 2025 · PMID 40456531
14Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study.RCT Nutrients, 2026 · PMID 42196985
15Heyndrickxia coagulans strain SANK70258 suppresses symptoms of upper respiratory tract infection via immune modulation: a randomized, double-blind, placebo-controlled, parallel-group, comparative study.RCT Front Immunol, 2024 · PMID 38957464

What changed

Every dated change to this page: what changed, who made it and why.

Change log

3 entries

Dated changes to this page
Date	Change	Who and why
Oct 21, 2026evidence, key facts, forms, studied doses, time to effect, FAQ, questions, related	Made the 2026 strain-specific meta-analysis the graded IBS row for Unique IS2 (2 trials, adults and children; grade B) and added three trials: Unique IS2 in 144 healthy adults with infrequent bowel movements (grade C), IDCC 1201 for sleep (78 adults; grade D) and SANK70258 for cold symptoms (79 adults; grade D). Added the two strains to the forms table, updated the funding facts, added time-to-effect rows and page questions, and replaced FAQ items that duplicated the page's own questions with strain choice, children and daily use. Interactions checked in LiverTox, LactMed (no probiotic entries), NCCIH and the Health Canada licence: no drug interactions documented, so the list stays empty. Not added: a 2024 BCP92 IBS trial (dose not in the abstract), a 2026 BC99 constipation trial (participant number not in the abstract) and a 2026 oral-health meta-analysis (pooled participant number not reported).	Writer: Kymata Health EditorialTrigger: A–Z audit against docs/supplements/AUDIT-STANDARD.md
Oct 14, 2026evidence	LBSC trial funding and affiliation (Advanced Enzyme Technologies) disclosed; funding key fact and insight updated	Writer: Kymata Health EditorialTrigger: adversarial review
Oct 14, 2026all	Initial editorial evidence review	Writer: Kymata Health EditorialTrigger: new page

Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.